Metrics as of 10/16/2026, 08:30 AM (Berlin time), refresh in progress.
Iambic Therapeutics Inc.
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and…
1D
+25.9%
1W
–
1M
–
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
FREE FLOAT
–
FLOAT SHARES
–
AVG. DAILY VOLUME (30D)
1,751,863
Secora Michael
Josephson Neil
Miller Thomas F.
Olson Peter A
Manby Frederick R
Iambic Therapeutics Inc. is a company in the Technology sector, Software - Application industry, headquartered in United States.
The IPO was on 15/10/2026; the stock trades on NASDAQ under the ticker IAM.
No, Iambic Therapeutics currently does not pay a dividend.
Clicking "Analyze stock" lets five strategies assess Iambic Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.